Irrespective of accomplishing a complete response with optimal induction therapy, minimal residual sickness usually persists, necessitating consolidation therapy to mitigate the risk of relapse by eradicating residual sickness. In individuals that have gained seven+3 induction therapy, consolidation therapy is initiated with significant-dose cytar